REGEN THERAPEUTICS PLC

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd

5. Date of the transaction and date on which the threshold is crossed or reached (v):

29th June 2009

6. Date on which issuer notified:

1st July 2009

7. Threshold(s) that is/are crossed or reached:

12% to 13%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code	GB00B28XMY25
Situation Previous to the triggering transaction (vi) –	
Number of Shares	3,622,093
Number of Voting Rights (viii)	3,622,093
Resulting situation after the triggering transaction (viii) –	
Number of Shares	3,648,093
Number of Voting Rights – Direct (x)	N/A
Number of Voting Rights – Indirect (xi)	3,648,093
% of voting rights – Direct	N/A
% of voting rights – Indirect	13.02

B: Financial Instruments

Resulting situation after the triggering transaction (x	xii)
Type of financial instrument	N/A
Expiration date (xiii)	N/A
Exercise/Conversion Period/Date (xiv)	N/A
Number of voting rights that may be acquired in instrument is exercised/converted	f the N/A
% of voting rights	N/A
C: Financial Instruments with similar economic effect to C	Qualifying Financial Instruments
Resulting situation after the triggering transaction	
Type of financial instrument	N/A
Exercise Price	N/A
Experation Date	N/A
Number of voting rights Instrument refers to	N/A
% of voting rights	N/A
Total (A+B+C)	
Number of voting rights	3,648,093
% of voting rights	13.02
9. Chain of controlled undertakings through which the voting r effectively held, if applicable (xv): Barclays Stockbrokers	
Proxy Voting:	
10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A
13. Additional information:	N/A
14. Contact name:	Geoff Smith
15. Contact telephone number:	0207 116 2913

For further information:

For further information, please contact:

Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited

Tel: 020 7628 3396